Login . Register .
Latest Trades
BrilliantOPENLONG$7.730KEPPEL CORPORATION LIMITED
supermonkeyCLOSEDSHORT-6.77%LIAN BENG GROUP LTD
supermonkeyCLOSEDSHORT-6.77%LIAN BENG GROUP LTD
Post Reply 
Kukusamy!! To market new drugs in India, global trials must include Indians !!
Author Message
11-10-2017 5:38 AM
EXBB Offline
Hall of Fame

Posts: 36,517
Reputation: 42
Surprised
To market new drugs in India, global trials must include Indians


https://m.timesofindia.com/india/to-market-new-drugs-in-india-global-trials-must-include-indians/articleshow/61029119.cms

[Image: 2dtrb6v.jpg]
[Image: 20r9tll.jpg]
Find all posts by this user Quote this message in a reply
11-10-2017 9:26 AM
talkingstocking Online
Senior Elite

Posts: 10,169
Reputation: 7
No need to sell to India lor!

Fake news found :

http://sgtalk.org/mybb/User-SmarTIndex

SgTalk allows the use of FAKE news as signature! thumbs up

30-6-2017 6:44 AMtester wrote  He is using the signature to state his belief. Not neccesarily based on fact
Find all posts by this user Quote this message in a reply
11-10-2017 9:32 AM
Avatar Offline
First Class Elite

Posts: 5,409
Reputation: 4
Where has that clown kukusamy gone?
Find all posts by this user Quote this message in a reply
13-10-2017 12:54 AM
greenlight Offline
Elite

Posts: 4,039
Reputation: 3
11-10-2017 9:32 AMAvatar wrote  Where has that clown kukusamy gone?

kukusamy is testing with his body!Rolling on the flor laughing
(This post was last modified: 13-10-2017 12:54 AM by greenlight.)
Find all posts by this user Quote this message in a reply
13-10-2017 12:58 AM
Kurusamy Offline
Senior Sheep

Posts: 497
Reputation: 3
Kurusamy says:

This is a brilliant policy by India's govt. It is only fair and sensible to include candidates of all races and nationalities when doing trial runs for drug testings.

I applaud this wise policy measure that demonstrates the efficacy of India's decision-making machinery.
Find all posts by this user Quote this message in a reply
Post Reply 
User(s) browsing this thread: 1 Guest(s)

Forum Jump:
Contact . Privacy . Rules .  RSS . Back-to-Top